Key Points
- Eugene Schneider, EVP, sold 5,812 shares on March 19 at an average price of $70.97 for total proceeds of $412,477.64, reducing his stake by 8.34% to 63,890 shares valued at about $4.53M.
- Schneider also sold 6,179 shares on Jan 30 at $83.45 and 9,302 shares on Jan 16 at $75.59, indicating multiple insider sales earlier this year.
- Ionis missed EPS (reported -$1.41 vs. -$1.23 est.) despite revenue beating estimates but down 10.6% YoY, while analysts have broadly raised price targets leaving a consensus "Moderate Buy" and an average target of $89.00.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eugene Schneider sold 5,812 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $70.97, for a total value of $412,477.64. Following the completion of the sale, the executive vice president directly owned 63,890 shares of the company's stock, valued at $4,534,273.30. The trade was a 8.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Eugene Schneider also recently made the following trade(s):
- On Friday, January 30th, Eugene Schneider sold 6,179 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $83.45, for a total value of $515,637.55.
- On Friday, January 16th, Eugene Schneider sold 9,302 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $75.59, for a total value of $703,138.18.
Ionis Pharmaceuticals Trading Down 0.3%
NASDAQ IONS opened at $70.79 on Tuesday. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $86.74. The business has a 50 day moving average price of $79.37 and a 200-day moving average price of $75.53. The company has a market cap of $11.69 billion, a price-to-earnings ratio of -29.01 and a beta of 0.31.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The firm had revenue of $203.33 million during the quarter, compared to the consensus estimate of $156.07 million. During the same quarter in the prior year, the business earned ($0.66) earnings per share. Ionis Pharmaceuticals's revenue for the quarter was down 10.6% on a year-over-year basis. As a group, equities analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on IONS shares. Wells Fargo & Company lifted their price objective on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an "overweight" rating in a report on Monday, January 5th. Needham & Company LLC upped their target price on shares of Ionis Pharmaceuticals from $90.00 to $103.00 and gave the stock a "buy" rating in a report on Wednesday, February 25th. Piper Sandler lifted their price target on Ionis Pharmaceuticals from $87.00 to $100.00 and gave the company an "overweight" rating in a research note on Friday, February 27th. Leerink Partners boosted their price objective on Ionis Pharmaceuticals from $102.00 to $104.00 and gave the stock an "outperform" rating in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada reissued an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $89.00.
Read Our Latest Report on IONS
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in IONS. Goldman Sachs Group Inc. increased its stake in Ionis Pharmaceuticals by 72.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company's stock valued at $19,686,000 after buying an additional 274,310 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Ionis Pharmaceuticals by 6.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company's stock worth $19,895,000 after buying an additional 39,794 shares in the last quarter. Focus Partners Wealth boosted its stake in shares of Ionis Pharmaceuticals by 30.1% in the 1st quarter. Focus Partners Wealth now owns 9,832 shares of the company's stock worth $297,000 after buying an additional 2,277 shares during the last quarter. Allworth Financial LP grew its holdings in shares of Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company's stock valued at $29,000 after acquiring an additional 517 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Ionis Pharmaceuticals by 3.9% in the second quarter. PNC Financial Services Group Inc. now owns 11,411 shares of the company's stock valued at $451,000 after acquiring an additional 424 shares in the last quarter. 93.86% of the stock is owned by institutional investors.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.
Since its founding in 1989 by Dr.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
